Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2023
Reporting Period: Second Quarter 2023
This filing announces the results of operations for the second quarter of 2023. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to assess performance, which exclude:
- Expenses related to acquisitions, restructuring, and cost reduction initiatives.
- Charges for intangible asset impairments and voluntary recalls.
- Fair value adjustments to contingent consideration.
- Certain regulatory costs and tax benefits associated with specified items.
- Intangible amortization expense.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It only confirms the announcement of Q2 2023 results and the use of non-GAAP adjustments for unusual or unpredictable factors.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business results. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing notes that non-GAAP adjustments account for unusual items such as voluntary recalls, regulatory costs, and tax position resolutions, implying these are areas of potential volatility.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net earnings, and cash flow figures.
- Compare GAAP and non-GAAP results to understand the impact of excluded items (e.g., restructuring, impairments, recalls).
- Verify the specific nature and magnitude of the "voluntary recall" and "regulatory costs" mentioned as adjustment factors.
- Check for any updated full-year guidance provided in the referenced press release.